Found: 25
Select item for more details and to access through your institution.
Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study.
- Published in:
- Journal of Cancer Research & Clinical Oncology, 2018, v. 144, n. 5, p. 945, doi. 10.1007/s00432-018-2604-x
- By:
- Publication type:
- Article
Recent Advances in the Use of Molecular Analyses to Inform the Diagnosis and Prognosis of Patients with Polycythaemia Vera.
- Published in:
- International Journal of Molecular Sciences, 2021, v. 22, n. 9, p. 5042, doi. 10.3390/ijms22095042
- By:
- Publication type:
- Article
The Cardiovascular Event Risk Associated with Tyrosine Kinase Inhibitors and the Lipid Profile in Patients with Chronic Myeloid Leukemia.
- Published in:
- Hematology Reports, 2024, v. 16, n. 1, p. 140, doi. 10.3390/hematolrep16010015
- By:
- Publication type:
- Article
Treatment‐free remission after dasatinib in patients with chronic myeloid leukaemia in chronic phase with deep molecular response: Final 5‐year analysis of DASFREE.
- Published in:
- British Journal of Haematology, 2023, v. 202, n. 5, p. 942, doi. 10.1111/bjh.18883
- By:
- Publication type:
- Article
Cauda equina syndrome secondary to extramedullary erythropoiesis in a transfusion‐dependent thalassemia patient following treatment with luspatercept: A case report.
- Published in:
- British Journal of Haematology, 2022, v. 199, n. 5, p. e30, doi. 10.1111/bjh.18470
- By:
- Publication type:
- Article
Validation of thrombotic risk factors in 1381 patients with essential thrombocythaemia: A multicentre retrospective real‐life study.
- Published in:
- British Journal of Haematology, 2022, v. 199, n. 1, p. 86, doi. 10.1111/bjh.18387
- By:
- Publication type:
- Article
The prognostic impact of non‐driver gene mutations and variant allele frequency in primary myelofibrosis.
- Published in:
- American Journal of Hematology, 2024, v. 99, n. 4, p. 755, doi. 10.1002/ajh.27203
- By:
- Publication type:
- Article
Hepatotoxicity as dose-limiting toxicity of the combination of bosutinib and atezolizumab in patients with chronic myeloid leukemia. Results of the ZEROLMC study.
- Published in:
- Annals of Hematology, 2024, v. 103, n. 10, p. 4045, doi. 10.1007/s00277-024-05662-7
- By:
- Publication type:
- Article
Low-risk polycythemia vera treated with phlebotomies: clinical characteristics, hematologic control and complications in 453 patients from the Spanish Registry of Polycythemia Vera.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Drug-to-drug interactions of tyrosine kinase inhibitors in chronic myeloid leukemia patients. Is it a real problem?
- Published in:
- Annals of Hematology, 2018, v. 97, n. 11, p. 2089, doi. 10.1007/s00277-018-3413-7
- By:
- Publication type:
- Article
Prognostic risk models for transplant decision-making in myelofibrosis.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Presence of Myeloid Mutations in Patients with Chronic Myeloid Leukemia Increases Risk of Cardiovascular Event on Tyrosine Kinase Inhibitor Treatment.
- Published in:
- Cancers, 2023, v. 15, n. 13, p. 3384, doi. 10.3390/cancers15133384
- By:
- Publication type:
- Article
Impact of Individual Comorbidities on Survival of Patients with Myelofibrosis.
- Published in:
- Cancers, 2022, v. 14, n. 9, p. N.PAG, doi. 10.3390/cancers14092331
- By:
- Publication type:
- Article
Thrombotic Risk Detection in Patients with Polycythemia Vera: The Predictive Role of DNMT3A/TET2/ASXL1 Mutations.
- Published in:
- Cancers, 2020, v. 12, n. 4, p. 934, doi. 10.3390/cancers12040934
- By:
- Publication type:
- Article
The risk of thrombosis in essential thrombocythemia is associated with the type of CALR mutation: A multicentre collaborative study.
- Published in:
- European Journal of Haematology, 2021, v. 106, n. 3, p. 371, doi. 10.1111/ejh.13561
- By:
- Publication type:
- Article
DASFREE: Treatment-Free Remission (TFR) After Discontinuation of Dasatinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) and Deep Molecular Response (DMR).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. S299, doi. 10.1016/j.clml.2019.07.253
- By:
- Publication type:
- Article
Treatment-Free Remission (TFR) Following Frontline Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): 192-Weeks Data from the ENESTfreedom Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. S288, doi. 10.1016/j.clml.2019.07.232
- By:
- Publication type:
- Article
ENESTfreedom 144-Week Update: Long-Term Treatment-Free Remission (TFR) Following Frontline Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2018, v. 18, p. S226, doi. 10.1016/j.clml.2018.07.099
- By:
- Publication type:
- Article
Treatment-Free Remission (TFR) in Patients with Chronic-Phase Chronic Myeloid Leukemia (CML-CP) and Stable Deep Molecular Response (DMR) Discontinuing Dasatinib (DASFREE).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2018, v. 18, p. S220, doi. 10.1016/j.clml.2018.07.090
- By:
- Publication type:
- Article
Prediction of major bleeding events in 1381 patients with essential thrombocythemia.
- Published in:
- International Journal of Hematology, 2023, v. 118, n. 5, p. 589, doi. 10.1007/s12185-023-03650-7
- By:
- Publication type:
- Article
Genetic Testing at Diagnosis Has Prognostic Value in Patients with Chronic Lymphocytic Leukemia including at Early Stages.
- Published in:
- Diagnostics (2075-4418), 2022, v. 12, n. 8, p. 1802, doi. 10.3390/diagnostics12081802
- By:
- Publication type:
- Article
Real‐world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea.
- Published in:
- Cancer (0008543X), 2022, v. 128, n. 13, p. 2441, doi. 10.1002/cncr.34195
- By:
- Publication type:
- Article
Biomarkers of Response to Venetoclax Therapy in Acute Myeloid Leukemia.
- Published in:
- International Journal of Molecular Sciences, 2024, v. 25, n. 3, p. 1421, doi. 10.3390/ijms25031421
- By:
- Publication type:
- Article
Molecular Studies for the Early Detection of Philadelphia-Negative Myeloproliferative Neoplasms.
- Published in:
- International Journal of Molecular Sciences, 2023, v. 24, n. 16, p. 12700, doi. 10.3390/ijms241612700
- By:
- Publication type:
- Article
Janus kinase inhibitor ruxolitinib in combination with nilotinib and prednisone in patients with myelofibrosis (RuNiC study): A phase Ib, multicenter study.
- Published in:
- EJHaem, 2023, v. 4, n. 2, p. 401, doi. 10.1002/jha2.685
- By:
- Publication type:
- Article